World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
42690
World Ranking
16878
National Ranking
45

Overview

Nir Peled is affiliated with Ben-Gurion University of the Negev in Israel and has an extensive publication record primarily in the field of Medicine with a focus on Pulmonary and Respiratory Medicine and Oncology. Their work spans various subfields including Molecular Biology, Cancer Research, and Radiology, Nuclear Medicine and Imaging.

The main topics addressed in their research include:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Colorectal Cancer Treatments and Studies
  • Cancer Genomics and Diagnostics
  • Radiomics and Machine Learning in Medical Imaging

Nir Peled's frequent publication venues encompass several leading journals in oncology and thoracic medicine:

  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Frontiers in Oncology
  • Cancer Research

Collaborations have been an essential aspect of their career, with repeated co-authorships involving researchers such as Waleed Kian, Laila C. Roisman, Elizabeth Dudnik, Alona Zer, and Maximilian J. Hochmair.

Recent notable papers include:

  • "Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer", 2020, Journal of Clinical Oncology
  • "Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%", 2021, Journal of Clinical Oncology
  • "Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer", 2020, New England Journal of Medicine
  • "Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer", 2021, Journal of Thoracic Oncology
  • "Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study", 2023, Journal of Clinical Oncology

Best Publications

  • Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

    Leena Gandhi;Delvys Rodríguez-Abreu;Shirish Gadgeel;Emilio Esteban

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    J. Mazieres;A. Drilon;A. Lusque;L. Mhanna

  • Volatile organic compounds of lung cancer and possible biochemical pathways.

    Meggie Hakim;Yoav Y. Broza;Orna Barash;Nir Peled

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

    Shirish Gadgeel;Delvys Rodríguez-Abreu;Giovanna Speranza;Emilio Esteban

  • Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50%

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong

  • Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

    Christian Rolfo;Philip C. Mack;Giorgio V. Scagliotti;Paul Baas

  • Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules

    Morad K. Nakhleh;Haitham Amal;Raneen Jeries;Yoav Y. Broza

  • Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

    Luis M. Seijo;Nir Peled;Daniel Ajona;Mattia Boeri

  • Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors

    E. Izumchenko;K. Paz;D. Ciznadija;I. Sloma

  • Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

    Alexa B. Schrock;Garrett M. Frampton;James Suh;Zachary R. Chalmers

  • Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

    Julie R Brahmer;Delvys Rodríguez-Abreu;Andrew G Robinson;Rina Hui

  • Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry

    Oliver Gautschi;Julie Milia;Thomas Filleron;Juergen Wolf

  • Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment.

    Nir Peled;Edward G Abinader;Giora Pillar;Dawood Sharif

  • Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.

    D. Rodríguez-Abreu;S.F. Powell;M.J. Hochmair;S. Gadgeel

  • ESR/ERS white paper on lung cancer screening

    Hans-Ulrich Kauczor;Lorenzo Bonomo;Mina Gaga;Kristiaan Nackaerts

  • Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

    Anne Marie C. Dingemans;Anne Marie C. Dingemans;Lizza E.L. Hendriks;Thierry Berghmans;Antonin Levy

Frequent Co-Authors

Martin Reck
Martin Reck LungenClinic Grosshansdorf
Hossam Haick
Hossam Haick Technion – Israel Institute of Technology
Siraj M. Ali
Siraj M. Ali Foundation Medicine
Fred R. Hirsch
Fred R. Hirsch Mount Sinai Hospital
Mary O'Brien
Mary O'Brien Royal Marsden NHS Foundation Trust
Paul A. Bunn
Paul A. Bunn University of Colorado Boulder
Garrett M. Frampton
Garrett M. Frampton Foundation Medicine
Peretz Lavie
Peretz Lavie Technion – Israel Institute of Technology
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens up a variety of online degree and career opportunities beyond the traditional MD path. Many healthcare professionals seek flexible, affordable ways to advance their education and expertise while balancing work and life commitments.

For nurses aiming to reach the highest levels of practice, cheap online dnp programs offer cost-effective options to earn a Doctor of Nursing Practice degree. Pharmacists can also benefit from flexible learning through accredited pharm d online programs, which prepare graduates for advanced roles in pharmacy and patient care.

The healthcare industry relies on skilled professionals in data management and administration. Those interested can choose a him degree online to pursue careers in managing health records, privacy, and compliance. Additionally, there is strong demand for experts in billing and insurance processes, with a medical coding certification serving as a gateway to roles in medical billing and coding.

These online degree pathways provide practical routes to fulfilling healthcare careers, making advanced education more accessible and affordable than ever.

Best Scientists Citing Nir Peled

Trending Scientists

Recently Published Articles